Company Filing History:
Years Active: 2006
Title: **Innovative Contributions of Kin Ming Lo in Immunogenicity Enhancement**
Introduction
Kin Ming Lo, based in Lexington, MA, has made significant strides in the field of immunology with a focus on enhancing the immunogenicity of protein and peptide antigens. As an inventor with a keen understanding of molecular biology, he has developed methods that could vastly improve vaccine efficacy and therapeutic strategies.
Latest Patents
Lo holds a patent titled "Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens." This innovative patent describes methods and compositions designed to enhance the immunogenicity of a preselected protein or peptide antigen in mammals. The technique involves fusing the antigen to an immunoglobulin heavy chain constant region, resulting in an Fc-antigen fusion protein. These fusion proteins bind to Fc receptors on antigen presenting cells, effectively targeting the antigens to these critical components of the immune system. Additionally, the patent outlines a family of adjuvants, including an Fc-adjuvant fusion protein, which can be used in combination with the Fc-antigen fusion proteins to enhance specific immune responses.
Career Highlights
Kin Ming Lo is associated with EMD Lexigen Research Center Corporation, where he has contributed to groundbreaking research in immunology. His work focuses on designing novel protein constructs to bolster the body's immune responses, which is a vital aspect of vaccine and therapeutic development. Through his research, he aims to address significant challenges in immunotherapy, establishing himself as a valuable inventor in the field.
Collaborations
Lo collaborates with esteemed colleagues such as Stephen D. Gillies and John S. Wesolowski, Jr., who contribute diverse expert knowledge in their respective fields. Together, they enhance the research initiatives at EMD Lexigen Research Center Corporation, fostering an innovative environment conducive to groundbreaking discoveries in medical biotechnology.
Conclusion
Kin Ming Lo's inventive approach to improving immunogenicity through Fc fusion proteins represents a critical advancement in biomedical science. His novel patent not only opens new avenues for vaccine development but also sets a foundation for potential therapeutic interventions. With his ongoing contributions and collaborations, Lo continues to make a significant impact in the realm of immunology and biotechnology.